Invasive Paranasal and Pulmonary Aspergillosis in a Post-COVID Patient with Diabetes

  • Soumalya Pradhan Intern IQ City Medical College and Hospital, Durgapur, West Bengal, India
  • Srijita Karmakar IQ City Medical College and Hospital, Durgapur, West Bengal, India
  • Souradeep Dutta IQ City Medical College and Hospital, Durgapur, West Bengal, India
Keywords: COVID-19, Diabetes, Fungal infection, Glucocorticoids, Invasive aspergillosis

Abstract

COVID-positive patients and those recovering from COVID affliction are more susceptible to fungal infections. It is especially
true in patients who are diabetic, on prolonged glucocorticoid medications and transplant patients. In critically ill patients,
invasive fungal infections have a bad prognosis resulting in grim figures of morbidity. Glucocorticoid medications may aggravate
hyperglycemia in patients with diabetes which present a favorable ground for fungal infections. In this case, we have come
across a patient who has a long-standing history of diabetes. She has been suffering from invasive pulmonary aspergillosis
while recovering from COVID-19. The diagnosis of invasive aspergillosis is difficult using clinical criteria, thus imaging modalities
are the mainstay for diagnosis. Intravenous voriconazole (400 mg BD tapered down to 200 mg) has been used to treat her
condition. Patients who are on glucocorticoids, have deteriorating pulmonary functions, and are diabetic have increased risk
of developing aspergillosis.

Author Biographies

Soumalya Pradhan Intern, IQ City Medical College and Hospital, Durgapur, West Bengal, India

Intern,

Srijita Karmakar, IQ City Medical College and Hospital, Durgapur, West Bengal, India

 Intern

Souradeep Dutta, IQ City Medical College and Hospital, Durgapur, West Bengal, India

 Intern

References

1. Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al.
Characterization of bacterial and fungal infections in hospitalized patients
with Coronavirus disease 2019 and factors associated with health careassociated
infections. Open Forum Infect Dis 2021;8:ofab201.
2. COVID-19 Stats India. Available from: https://www.covid19.who.int/
region/searo/country/in.
3. Pandey SK, Sharma V. World diabetes day 2018: Battling the emerging
epidemic of diabetic retinopathy. Indian J Ophthalmol 2018;66:1652-3.
4. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K,
Gilchrist M, et al. Bacterial and fungal coinfection in individuals
with coronavirus: A rapid review to support COVID-19 antimicrobial
prescribing. Clin Infect Dis 2020;71:2459-68.
5. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al.
SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity
in invasive fungal infections of the maxillofacial region? A retrospective,
multi-centric analysis. J Maxillofac Oral Surg 2021;2021;1-8.
6. Clinical Management Protocol for COVID-19. Available from:
https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagement
ProtocolforCOVID19adultsdated24052021.pdf.
7. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive
effects of glucocorticoids, recent developments and mechanistic insights.
Mol Cell Endocrinol 2011;335:2-13.
8. Segrelles-Calvo G, Araújo GR, Llopis-Pastor E, Carrillo J, Hernández-
Hernández M, Rey L, et al. Prevalence of opportunistic invasive
aspergillosis in COVID-19 patients with severe pneumonia. Mycoses
2021;64:144-51.
Published
2021-10-01